Serabelisib

DB14935InvestigationalSmall molecule

Serabelisib is under investigation in clinical trial NCT02625259 (A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117)...

Mechanism: Pharmacologically active on Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
Curator reviewed
Formula / weight: C₁₉H₁₇N₅O₃ · 363.377 g/mol (avg)
Code names: MLN1117 · TAK-117

Resolves to

Compound

UNII43J9Q56T3WCAS1268454-23-4ChEMBLCHEMBL3935857

Structure

InChIKeyBLGWHBSBBJNKJO-UHFFFAOYSA-NSMILESNC1=NC2=CC(=CC=C2O1)C1=CN2C(C=C1)=NC=C2C(=O)N1CCOCC1

Targets

P42336PIK3CA

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

13Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Serabelisib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account